Drug Research

The traditional pharmaceutical research and development model has long been characterized by high costs, long timelines, and a high rate of failure. For every drug that successfully reaches the market, thousands of candidates fall by the wayside during the...

Novartis has finalized a significant collaboration agreement with Antares Therapeutics to advance the discovery and development of small molecule therapies for various cancers. The deal, which could reach a total value of $1.9 billion, focuses on addressing oncology targets...

Continuous manufacturing drug formulation represents the most significant leap in pharmaceutical engineering in over a century, fundamentally altering how medications are conceived, developed, and delivered to the global market. For decades, the industry operated under the batch manufacturing paradigm,...

The pharmaceutical industry is currently witnessing a transformative shift from a mass-production model to a patient-centric approach, driven largely by the innovation of 3D printed dosage forms advancing precision medicine. For over a century, the standard of care has...

The pharmaceutical industry is currently undergoing a data-driven revolution that is fundamentally changing how medications are designed and optimized. For decades, drug development was a linear process that culminated in randomized controlled trials (RCTs). While RCTs are essential for...

Bayer has strengthened its pharmaceutical and ophthalmology portfolio through two separate transactions, completing the acquisition of Perfuse Therapeutics while also entering a collaboration agreement with Iambic Therapeutics. The moves provide Bayer with full ownership of Perfuse’s lead asset, PER-001,...

The US Department of Health and Human Services (HHS) has outlined a new strategy aimed at reinforcing the country’s position in pharmaceutical research as competition from China intensifies. Through an initiative called Operation Trailblazer, HHS plans to introduce measures...